Stocktoria
RHYTHM PHARMACEUTICALS, INC. RYTM
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-10-05
RHYTHM PHARMACEUTICALS, INC. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -101.2% | -204.0% | -238.1% | -757.9% | -5391.9% |
| Net margin | -103.6% | -200.3% | -238.5% | -766.2% | -2207.1% |
| FCF margin | -61.5% | -87.5% | -175.9% | -734.9% | -4642.9% |
| Return on assets | -40.9% | -66.4% | -55.5% | -47.4% | -21.1% |
| Return on equity | -141.3% | -1199.3% | -108.8% | -68.5% | -24.5% |
| Debt / equity | 0.73× | 4.98× | 0.63× | — | — |
| Current ratio | 4.41 | 3.24 | 5.58 | 8.90 | 7.10 |
| Revenue growth | 45.8% | 68.1% | 227.6% | 649.5% | — |
Source: SEC EDGAR filings · CIK 0001649904 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.